<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199585</url>
  </required_header>
  <id_info>
    <org_study_id>18193A</org_study_id>
    <nct_id>NCT04199585</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Lu AF95245 in Healthy Young Men</brief_title>
  <official_title>Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending Oral Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF95245 and Open-label Crossover Study to Investigate Intra-subject Variability, Effect of Food on Lu AF95245, and Metabolic Profile of [14C]-Lu AF95245 in Healthy Young Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and tolerability of Lu AF95245 and
      what the body does to Lu AF95245 after swallowing single doses of the drug
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided in two parts, Part A and Part B:

      Part A: interventional, randomized, double-blind, sequential-group, placebo-controlled,
      single-ascending oral dose study in healthy young men.

      Part A will consist of up to 6 cohorts (Cohorts A1 to A6) with 9 subjects in each cohort. In
      each cohort, the subjects will be randomised to receive a single oral dose of Lu AF95245 or
      placebo (ratio 6:3)

      Part B: interventional, randomized, open-label, three-period crossover study to investigate
      intra-subject variability, effect of food and mass balance and metabolic profile in healthy
      young men. Part B will be initiated when a anticipated therapeutically relevant dose
      confirmed to be safe and well-tolerated has been identified in Part A; this dose will be used
      in Part B. Part B is divided into 3 dosing periods and subjects will be randomised to 1 of 3
      groups (Groups B1, B2, and B3) with 4 subjects in each group and the groups will be running
      in parallel.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    new safety data from another study
  </why_stopped>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Actual">February 19, 2020</completion_date>
  <primary_completion_date type="Actual">February 16, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Cohort A: sequential, cohort B parallel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters and physical examination)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-inf) Lu AF95245</measure>
    <time_frame>From 0 to 96 hours</time_frame>
    <description>Area under the plasma concentration time curve from zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax Lu AF95245</measure>
    <time_frame>From 0 to 96 hours</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F Lu AF95245</measure>
    <time_frame>From 0 to 96 hours</time_frame>
    <description>Oral clearance for Lu AF95245 in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total recovery of the administered dose (% of dose in urine and faeces)</measure>
    <time_frame>From 0 to Day 14</time_frame>
    <description>Excretion of labelled Lu AF95245 in urine and faeces</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort A: single-ascending oral dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts A1 to A6, single ascending dose, with 9 subjects in each cohort, sequential</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: (fasting/fed conditions)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Groups B1, B2, and B3, with 4 subjects in each group and the groups will be running in parallel.
B1: fed-fasting-fasting condition (spiked dosage)
B2: fasting-fed-fasting condition (spiked dosage)
B3: fasting-fasting-fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF95245</intervention_name>
    <description>solution, single dose, orally</description>
    <arm_group_label>Cohort A: single-ascending oral dose</arm_group_label>
    <arm_group_label>Cohort B: (fasting/fed conditions)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF95245 14C radiolabelled spiked dosage</intervention_name>
    <description>solution, single dose, orally</description>
    <arm_group_label>Cohort B: (fasting/fed conditions)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>solution, single dose, orally</description>
    <arm_group_label>Cohort A: single-ascending oral dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, young, non-smoking men with a body mass index (BMI) ≥18.5 kg/m2 and ≤30 kg/m2
             at the Screening Visit.

        Exclusion Criteria:

          -  The subject has any concurrent disorder that may affect the particular target or
             absorption, distribution, or elimination of the IMP.

        Other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS Netherlands BV</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

